Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kabitz, H.-J.
Right arrow Articles by Windisch, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kabitz, H.-J.
Right arrow Articles by Windisch, W.
(Chest. 2006;130:1496-1502.)
© 2006 American College of Chest Physicians

Impact of Impaired Inspiratory Muscle Strength on Dyspnea and Walking Capacity in Sarcoidosis*

Hans-Joachim Kabitz, MD; Felix Lang; Stephan Walterspacher; Stephan Sorichter, MD; Joachim Müller-Quernheim, MD and Wolfram Windisch, MD

* From the Department of Pneumology, University Hospital, Freiburg, Germany.

Correspondence to: Wolfram Windisch, MD, Department of Pneumology, University Hospital Freiburg, Killianstrasse 5, D-79106 Freiburg, Germany; e-mail: windisch{at}med1.ukl.uni-freiburg.de

Abstract

Background: Dyspnea and fatigue are frequent but poorly understood symptoms in sarcoidosis patients. This study was aimed at assessing the clinical impact of inspiratory muscle impairment on dyspnea and exercise tolerance. This is the first study using nonvolitional tests that are independent of the patient’s cooperation and motivation in addition to volitional tests of inspiratory muscle strength in patients with sarcoidosis.

Methods: Peak maximal inspiratory mouth pressure (PImaxPEAK), maximal inspiratory pressure sustained for 1.0 s (PImax1.0), twitch mouth pressure (TwPmo), lung function test results, blood gas measurements, 6-min walking distance (6MWD), and Borg dyspnea scale (BDS) scores were assessed in 24 male sarcoidosis patients and 24 healthy male control subjects matched for age and body mass index.

Results: Mean (± SD) PImaxPEAK (95.2 ± 25.3% vs 124.6 ± 23.4% predicted, respectively; p < 0.001) and PImax1.0 (85.6 ± 31.4% vs 125.8 ± 26.8% predicted, respectively; p < 0.001) were lower in sarcoidosis patients compared to control subjects. TwPmo tended to be lower in sarcoidosis patients, and there were three patients who had TwPmo values of < 1.0 kPa, which is a strong indicator of inspiratory muscle weakness. The mean 6MWD was 582 ± 97 m in sarcoidosis patients and 638 ± 65 in control subjects (p = 0.025). The mean BDS score was higher in sarcoidosis patients (3.3 ± 1.7 vs 0.2 ± 0.5, respectively; p < 0.001). Compared to maximal inspiratory pressure, lung function parameters, and blood gas levels, TwPmo was the strongest predictor for 6MWD (r = 0.663; p = 0.003) and BDS score (r = 0.575; p = 0.012) in sarcoidosis patients following multiple linear regression analysis.

Conclusions: Impairment of inspiratory muscle strength occurs in sarcoidosis patients, and has been suggested to be an important factor causing dyspnea and reduced walking capacity, but this is only reliably detectable when using nonvolitional tests of inspiratory muscle strength.

Key Words: inspiratory muscle strength • maximal inspiratory pressure • muscle weakness • phrenic nerve stimulation • twitch mouth pressure






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American College of Chest Physicians.